Dose regimen rationale for panitumumab in cancer patients: to be based on body weight or not
MZ Liao, M Berkhout, H Prenen, S Dutta… - Clinical pharmacology …, 2020 - Taylor & Francis
Introduction Body weight can affect exposure, safety and efficacy of antibody-based
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
MZ Liao, M Berkhout, H Prenen… - Clinical …, 2020 - search.proquest.com
Introduction: Body weight can affect exposure, safety and efficacy of antibody-based
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
Dose regimen rationale for panitumumab in cancer patients: to be based on body weight or not
MZ Liao, M Berkhout, H Prenen… - … Place of publication …, 2020 - repository.uantwerpen.be
Introduction: Body weight can affect exposure, safety and efficacy of antibody-based
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
MZ Liao, M Berkhout, H Prenen… - Clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Body weight can affect exposure, safety and efficacy of antibody-based
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not.
MZ Liao, M Berkhout, H Prenen, S Dutta… - Clinical Pharmacology …, 2020 - go.gale.com
Introduction: Body weight can affect exposure, safety and efficacy of antibody-based
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
MZ Liao, M Berkhout, H Prenen, S Dutta… - Clinical Pharmacology …, 2020 - dovepress.com
Results: After administration of panitumumab 6 mg/kg, C max and C min increased with
increasing body weight; the mean C max and C min for patients weighing< 65 kg (lower …
increasing body weight; the mean C max and C min for patients weighing< 65 kg (lower …
[HTML][HTML] Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
MZ Liao, M Berkhout, H Prenen, S Dutta… - Clinical Pharmacology …, 2020 - ncbi.nlm.nih.gov
Results After administration of panitumumab 6 mg/kg, C max and C min increased with
increasing body weight; the mean C max and C min for patients weighing< 65 kg (lower …
increasing body weight; the mean C max and C min for patients weighing< 65 kg (lower …
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not.
MZ Liao, M Berkhout, H Prenen, S Dutta… - Clinical Pharmacology …, 2020 - europepmc.org
Results After administration of panitumumab 6 mg/kg, C max and C min increased with
increasing body weight; the mean C max and C min for patients weighing< 65 kg (lower …
increasing body weight; the mean C max and C min for patients weighing< 65 kg (lower …
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
MZ Liao, M Berkhout, H Prenen… - Clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Introduction Body weight can affect exposure, safety and efficacy of antibody-based
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …
therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved …